Anticancer effect of SZC017, a novel derivative of oleanolic acid, on human gastric cancer cells

Gao,Lei; Xu,Zhen; Wang,Yan; Sun,Bin; Song,Zhicheng; Yang,Bining; Liu,Xu; Lin,Yuan; Peng,Jinyong; Han,Guozhu; Wang,Shisheng; Tang,Zeyao

doi:10.3892/or.2015.4447

Anticancer effect of SZC017, a novel derivative of oleanolic acid, on human gastric cancer cells

Authors:
- Lei Gao
- Zhen Xu
- Yan Wang
- Bin Sun
- Zhicheng Song
- Bining Yang
- Xu Liu
- Yuan Lin
- Jinyong Peng
- Guozhu Han
- Shisheng Wang
- Zeyao Tang
View Affiliations

Affiliations: Department of Pharmacology, Dalian Medical University, Dalian, Liaoning 116044, P.R. China, College of Pharmaceutical Science and Technology, Dalian University of Technology, Dalian, Liaoning 116024, P.R. China
Published online on: November 25, 2015 https://doi.org/10.3892/or.2015.4447
Pages: 1101-1108

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oleanolic acid (OA) and its several derivatives possess chemopreventive and chemotherapeutic functions against a series of cancer types. Many chemotherapeutic compounds are effective in improving the quality of life and prolonging the survival of patients with gastric cancer, therefore progress in the treatment of gastric cancer, especially the anticancer effects of OA derivatives must be achieved. The inhibitory effect of SZC017, a newly synthesized derivative of OA, on cell viability was determined by MTT assay. Furthermore, flow cytometry, transmission electron microscopy, and western blot analysis revealed that the inhibition of cell viability by OA was mediated by triggering the intrinsic apoptosis of gastric cancer cells, and inducing S phase arrest of SGC7901 cells. Mechanistically, SZC017 was effective against gastric cancer cells via inhibiting Akt/NF‑κB signaling and topoisomerase I and IIα proteins. Taken together, our data indicate that SZC017 may be a potential chemotherapeutic agent against gastric cancer cells.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Liby KT, Yore MM and Sporn MB: Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer. 7:357–369. 2007. View Article : Google Scholar : PubMed/NCBI
3	Pollier J and Goossens A: Oleanolic acid. Phytochemistry. 77:10–15. 2012. View Article : Google Scholar : PubMed/NCBI
4	Shanmugam MK, Dai X, Kumar AP, Tan BK, Sethi G and Bishayee A: Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: Preclinical and clinical evidence. Cancer Lett. 346:206–216. 2014. View Article : Google Scholar : PubMed/NCBI
5	Bishayee A, Mandal A, Thoppil RJ, Darvesh AS and Bhatia D: Chemopreventive effect of a novel oleanane triterpenoid in a chemically induced rodent model of breast cancer. Int J Cancer. 133:1054–1063. 2013. View Article : Google Scholar : PubMed/NCBI
6	Deeb D, Gao X, Liu Y, Jiang D, Divine GW, Arbab AS, Dulchavsky SA and Gautam SC: Synthetic triterpenoid CDDO prevents the progression and metastasis of prostate cancer in TRAMP mice by inhibiting survival signaling. Carcinogenesis. 32:757–764. 2011. View Article : Google Scholar : PubMed/NCBI
7	Konopleva M, Contractor R, Kurinna SM, Chen W, Andreeff M and Ruvolo PP: The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells. Leukemia. 19:1350–1354. 2005. View Article : Google Scholar : PubMed/NCBI
8	Shao Y, Gao Z, Marks PA and Jiang X: Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA. 101:18030–18035. 2004. View Article : Google Scholar : PubMed/NCBI
9	Boucher D, Blais V and Denault JB: Caspase-7 uses an exosite to promote poly(ADP ribose) polymerase 1 proteolysis. Proc Natl Acad Sci USA. 109:5669–5674. 2012. View Article : Google Scholar : PubMed/NCBI
10	Cory S and Adams JM: Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell. 8:5–6. 2005. View Article : Google Scholar : PubMed/NCBI
11	Qiu P, Guan H, Dong P, Li S, Ho CT, Pan MH, McClements DJ and Xiao H: The p53-, Bax-and p21-dependent inhibition of colon cancer cell growth by 5-hydroxy polymethoxyflavones. Mol Nutr Food Res. 55:613–622. 2011. View Article : Google Scholar : PubMed/NCBI
12	Kim W, Yang HJ, Youn H, Yun YJ, Seong KM and Youn B: Myricetin inhibits Akt survival signaling and induces Bad-mediated apoptosis in a low dose ultraviolet (UV)-B-irradiated HaCaT human immortalized keratinocytes. J Radiat Res (Tokyo). 51:285–296. 2010. View Article : Google Scholar
13	Wang X, Bai H, Zhang X, Liu J, Cao P, Liao N, Zhang W, Wang Z and Hai C: Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis. Carcinogenesis. 34:1323–1330. 2013. View Article : Google Scholar : PubMed/NCBI
14	Gilmore TD and Herscovitch M: Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene. 25:6887–6899. 2006. View Article : Google Scholar : PubMed/NCBI
15	Li TK and Liu LF: Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol. 41:53–77. 2001. View Article : Google Scholar : PubMed/NCBI
16	Nitiss JL: DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer. 9:327–337. 2009. View Article : Google Scholar : PubMed/NCBI
17	Curtin NJ: Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer. Br J Pharmacol. 169:1745–1765. 2013. View Article : Google Scholar : PubMed/NCBI
18	Ghavami S, Hashemi M, Ande SR, Yeganeh B, Xiao W, Eshraghi M, Bus CJ, Kadkhoda K, Wiechec E, Halayko AJ, et al: Apoptosis and cancer: Mutations within caspase genes. J Med Genet. 46:497–510. 2009. View Article : Google Scholar : PubMed/NCBI
19	Call JA, Eckhardt SG and Camidge DR: Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol. 9:1002–1011. 2008. View Article : Google Scholar : PubMed/NCBI
20	Ravanan P, Sano R, Talwar P, Ogasawara S, Matsuzawa S, Cuddy M, Singh SK, Rao GS, Kondaiah P and Reed JC: Synthetic triterpenoid cyano enone of methyl boswellate activates intrinsic, extrinsic, and endoplasmic reticulum stress cell death pathways in tumor cell lines. Mol Cancer Ther. 10:1635–1643. 2011. View Article : Google Scholar : PubMed/NCBI
21	Hyer ML, Shi R, Krajewska M, Meyer C, Lebedeva IV, Fisher PB and Reed JC: Apoptotic activity and mechanism of 2-cyano-3, 12-dioxoolean-1,9-dien-28-oic-acid and related synthetic triterpenoids in prostate cancer. Cancer Res. 68:2927–2933. 2008. View Article : Google Scholar : PubMed/NCBI
22	Inoue S, Snowden RT, Dyer MJ and Cohen GM: CDDO induces apoptosis via the intrinsic pathway in lymphoid cells. Leukemia. 18:948–952. 2004. View Article : Google Scholar : PubMed/NCBI
23	Altomare DA and Testa JR: Perturbations of the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464. 2005. View Article : Google Scholar : PubMed/NCBI
24	Ling X, Konopleva M, Zeng Z, Ruvolo V, Stephens LC, Schober W, McQueen T, Dietrich M, Madden TL and Andreeff M: The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling. Cancer Res. 67:4210–4218. 2007. View Article : Google Scholar : PubMed/NCBI
25	Dai S, Zheng Y, Chen B, Gao M, Zhang Y, Zhang L, Gong W and He F: Two Gln187 mutants of human soluble APRIL inhibit proliferation of lung carcinoma A549 cells. Acta Biochim Pol. 56:703–710. 2009.PubMed/NCBI
26	Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91:231–241. 1997. View Article : Google Scholar : PubMed/NCBI
27	Ahmad A, Biersack B, Li Y, Kong D, Bao B, Schobert R, Padhye SB and Sarkar FH: Targeted regulation of PI3K/Akt/mTOR/NF-κB signaling by indole compounds and their derivatives: Mechanistic details and biological implications for cancer therapy. Anticancer Agents Med Chem. 13:1002–1013. 2013. View Article : Google Scholar : PubMed/NCBI
28	Hayden MS and Ghosh S: Shared principles in NF-kappaB signaling. Cell. 132:344–362. 2008. View Article : Google Scholar : PubMed/NCBI
29	Tully JE, Nolin JD, Guala AS, Hoffman SM, Roberson EC, Lahue KG, van der Velden J, Anathy V, Blackwell TS and Janssen-Heininger YM: Cooperation between classical and alternative NF-κB pathways regulates proinflammatory responses in epithelial cells. Am J Respir Cell Mol Biol. 47:497–508. 2012. View Article : Google Scholar : PubMed/NCBI
30	Manna S, Singha B, Phyo SA, Gatla HR, Chang TP, Sanacora S, Ramaswami S and Vancurova I: Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKalpha. J Immunol. 191:2837–2846. 2013. View Article : Google Scholar : PubMed/NCBI
31	Murray RZ and Norbury C: Proteasome inhibitors as anti-cancer agents. Anticancer Drugs. 11:407–417. 2000. View Article : Google Scholar : PubMed/NCBI
32	Chen G, Han K, Xu X, Du X, Zhang Z, Tang J, Shi M, Wang M, Li J, Cao B, et al: An anti-leishmanial thiadiazine agent induces multiple myeloma cell apoptosis by suppressing the nuclear factor kappaB signalling pathway. Br J Cancer. 110:63–70. 2014. View Article : Google Scholar :
33	Buss H, Dörrie A, Schmitz ML, Hoffmann E, Resch K and Kracht M: Constitutive and interleukin-1-inducible phosphorylation of p65 NF-κB at serine 536 is mediated by multiple protein kinases including IκB kinase (IKK)-α, IKKβ, IKKε, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription. J Biol Chem. 279:55633–55643. 2004. View Article : Google Scholar : PubMed/NCBI
34	Deng WG, Zhu Y and Wu KK: Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha-induced cyclooxy-genase-2 promoter activation. J Biol Chem. 278:4770–4777. 2003. View Article : Google Scholar
35	Zhong H, SuYang H, Erdjument-Bromage H, Tempst P and Ghosh S: The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell. 89:413–424. 1997. View Article : Google Scholar : PubMed/NCBI
36	Lagadec P, Griessinger E, Nawrot MP, Fenouille N, Colosetti P, Imbert V, Mari M, Hofman P, Czerucka D, Rousseau D, et al: Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells. Br J Cancer. 98:335–344. 2008. View Article : Google Scholar : PubMed/NCBI
37	Nakanishi C and Toi M: Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 5:297–309. 2005. View Article : Google Scholar : PubMed/NCBI
38	Xu Y and Villalona-Calero MA: Irinotecan: Mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol. 13:1841–1851. 2002. View Article : Google Scholar : PubMed/NCBI
39	Vos SM, Tretter EM, Schmidt BH and Berger JM: All tangled up: How cells direct, manage and exploit topoisomerase function. Nat Rev Mol Cell Biol. 12:827–841. 2011. View Article : Google Scholar : PubMed/NCBI
40	Pommier Y: Topoisomerase I inhibitors: Camptothecins and beyond. Nat Rev Cancer. 6:789–802. 2006. View Article : Google Scholar : PubMed/NCBI